The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study
Helle H Nielsen, Hans C Beck, Lars P Kristensen, Mark Burton, Tunde Csepany, Magdolna Simo, Peter Dioszeghy, Tobias Sejbaek, Manuela Grebing, Niels H H Heegaard, Zsolt Illes, Helle H Nielsen, Hans C Beck, Lars P Kristensen, Mark Burton, Tunde Csepany, Magdolna Simo, Peter Dioszeghy, Tobias Sejbaek, Manuela Grebing, Niels H H Heegaard, Zsolt Illes
Abstract
Objectives: Inflammatory demyelinating diseases of the CNS comprise a broad spectrum of diseases like neuromyelitis optica (NMO), NMO spectrum disorders (NMO-SD) and multiple sclerosis (MS). Despite clear classification criteria, differentiation can be difficult. We hypothesized that the urine proteome may differentiate NMO from MS.
Methods: The proteins in urine samples from anti-aquaporin 4 (AQP4) seropositive NMO/NMO-SD patients (n = 32), patients with MS (n = 46) and healthy subjects (HS, n = 31) were examined by quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) after trypsin digestion and iTRAQ labelling. Immunoglobulins (Ig) in the urine were validated by nephelometry in an independent cohort (n = 9-10 pr. groups).
Results: The analysis identified a total of 1112 different proteins of which 333 were shared by all 109 subjects. Cluster analysis revealed differences in the urine proteome of NMO/NMO-SD compared to HS and MS. Principal component analysis also suggested that the NMO/NMO-SD proteome profile was useful for classification. Multivariate regression analysis revealed a 3-protein profile for the NMO/NMO-SD versus HS discrimination, a 6-protein profile for NMO/NMO-SD versus MS discrimination and an 11-protein profile for MS versus HS discrimination. All protein panels yielded highly significant ROC curves (AUC in all cases >0.85, p≤0.0002). Nephelometry confirmed the presence of increased Ig-light chains in the urine of patients with NMO/NMO-SD.
Conclusion: The urine proteome profile of patients with NMO/NMO-SD is different from MS and HS. This may reflect differences in the pathogenesis of NMO/NMO-SD versus MS and suggests that urine may be a potential source of biomarkers differentiating NMO/NMO-SD from MS.
Conflict of interest statement
Competing Interests: Helle H. Nielsen has received travel funding and speaker honoraria from and served on advisory boards for Merck-Serono, Novartis Healthcare, Biogen Idec, Genzyme Denmark, Teva Denmark and UCB Nordic. Hans C. Beck declares no potential conflicts of interest. Lars P. Kristensen declares no potential conflicts of interest. Mark Burton has nothing to declare. Tunde Csepany has received speaker honoraria/congress expense compensations from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Teva. Magdolna Simo has received compensation for consulting services and speaking from Biogen Idec, Merck–Serono, Novartis, Sanofi–Aventis, and Teva Pharmaceutical Industries Ltd. Peter Dioszeghy has received compensation for consulting services from Biogen, Novartis, and Teva Pharmaceutical Industries Ltd. Tobias Sejbæk has received travel funding and speaker honoraria from Merck-Serono, Novartis Healthcare, Biogen Idec, Genzyme Denmark and Teva Denmark. Manuela Grebing declares no potential conflicts of interest. Niels H. H. Heegaard declare no conflicts of interest. Zsolt Illes has received compensation for consulting services and speaking from Bayer–Schering, Biogen–Idec, Merck–Serono, Novartis, Sanofi–Aventis, and Teva Pharmaceutical Industries Ltd. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain: a journal of neurology. 2002;125(Pt 7):1450–61. Epub 2002/06/22. .
- Illes Z. Pathogenesis, diagnosis and treatment of neuromyelitis optica: Changing concept of an old disease. Clinical and Experimental Neuroimmunology. 2010;1(3):103–23. 10.1111/j.1759-1961.2010.00011.x
- Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019–32. Epub 2010/06/10. 10.1111/j.1468-1331.2010.03066.x .
- Carroll W, Saida T, Kim H, Kira J, Kermode A, Tsai C, et al. A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica). Multiple sclerosis. 2013. Epub 2013/01/18. 10.1177/1352458512471092 .
- Sato DK, Callegaro D, Lana-Peixoto MA, Nakashima I, Fujihara K. Seronegative Neuromyelitis Optica Spectrum–-the challenges on disease definition and pathogenesis. Arquivos de neuro-psiquiatria. 2014;72(6):445–50. .
- Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of neurology. 2014;261(1):1–16. 10.1007/s00415-013-7169-7
- Jiang S, Lu Q, Hu S, Chen Y, Liu X, Yang Y, et al. Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients. Genetics and molecular research: GMR. 2014;13(AOP). 10.4238/2014.February.14.3 .
- Jiang S, Wu J, Yang Y, Liu J, Ding Y, Ding M. Proteomic analysis of the cerebrospinal fluid in multiple sclerosis and neuromyelitis optica patients. Molecular medicine reports. 2012;6(5):1081–6. 10.3892/mmr.2012.1025 .
- Komori M, Matsuyama Y, Nirasawa T, Thiele H, Becker M, Alexandrov T, et al. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Annals of neurology. 2012;71(5):614–23. Epub 2012/04/24. 10.1002/ana.22633 .
- Rodriguez-Suarez E, Siwy J, Zurbig P, Mischak H. Urine as a source for clinical proteome analysis: from discovery to clinical application. Biochimica et biophysica acta. 2014;1844(5):884–98. 10.1016/j.bbapap.2013.06.016 .
- Kentsis A, Monigatti F, Dorff K, Campagne F, Bachur R, Steen H. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clinical applications. 2009;3(9):1052–61. 10.1002/prca.200900008
- Mischak H, Kolch W, Aivaliotis M, Bouyssie D, Court M, Dihazi H, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clinical applications. 2010;4(4):464–78. 10.1002/prca.200900189
- Berger RP, Kochanek PM. Urinary S100B concentrations are increased after brain injury in children: A preliminary study. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2006;7(6):557–61. .
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–9. Epub 2006/05/24. 10.1212/01.wnl.0000216139.44259.74 .
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 2011;69(2):292–302. Epub 2011/03/10. 10.1002/ana.22366
- Beck HC, Gosau M, Kristensen LP, Morsczeck C. A site-specific phosphorylation of the focal adhesion kinase controls the formation of spheroid cell clusters. Neurochemical research. 2014;39(7):1199–205. 10.1007/s11064-014-1298-y .
- Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B. 1995;1:289–300.
- Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics. 2002;18(1):207–8. .
- Steen SO, Iversen LV, Carlsen AL, Burton M, Nielsen CT, Jacobsen S, et al. The circulating cell-free microRNA profile in systemic sclerosis is distinct from both healthy controls and systemic lupus erythematosus. The Journal of rheumatology. 2015;42(2):214–21. 10.3899/jrheum.140502 .
- Rouillon J, Zocevic A, Leger T, Garcia C, Camadro JM, Udd B, et al. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromuscular disorders: NMD. 2014;24(7):563–73. 10.1016/j.nmd.2014.03.012 .
- Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015. 10.1212/WNL.0000000000001729 .
- Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. The New England journal of medicine. 1998;338(5):278–85. .
- Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Journal of autoimmunity. 2014;48–49:134–42. 10.1016/j.jaut.2014.01.022 .
- Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of neurology. 2000;47(6):707–17. .
- Aradi M, Koszegi E, Orsi G, Perlaki G, Trauninger A, Toth A, et al. Quantitative MRI analysis of the brain after twenty-two years of neuromyelitis optica indicates focal tissue damage. European neurology. 2013;69(4):221–5. 10.1159/000345799 .
- Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain: a journal of neurology. 2005;128(Pt 7):1667–76. 10.1093/brain/awh486 .
- Owens GP, Bennett JL, Gilden DH, Burgoon MP. The B cell response in multiple sclerosis. Neurological research. 2006;28(3):236–44. 10.1179/016164106X98099 .
- Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Annals of neurology. 2000;47(6):694–706. .
- Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Annals of neurology. 1981;10(2):149–58. 10.1002/ana.410100205 .
- Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature reviews Immunology. 2004;4(2):89–99. 10.1038/nri1266 .
- Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin–4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain: a journal of neurology. 2007;130(Pt 5):1235–43. Epub 2007/04/24. 10.1093/brain/awm062 .
- Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin–4 in the long-term course of neuromyelitis optica. Brain: a journal of neurology. 2008;131(Pt 11):3072–80. 10.1093/brain/awn240
- Kitley J, Leite MI, Kuker W, Quaghebeur G, George J, Waters P, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA neurology. 2013;70(11):1375–81. 10.1001/jamaneurol.2013.3890 .
- Malik R, Lewis A, Cree BA, Ratelade J, Rossi A, Verkman AS, et al. Transient hyperckemia in the setting of neuromyelitis optica (NMO). Muscle & nerve. 2014;50(5):859–62. 10.1002/mus.24298
- Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome biology. 2006;7(9):R80 10.1186/gb-2006-7-9-R80
Source: PubMed